BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during ...
A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer
Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we ...
BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for ...
CIC bioGUNE leads a study showing that multi-omic data can identify silent and stable risk profiles in healthy individuals The study, conducted using local cohorts from the Basque Country, ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with ...
Using proprietary CIC text-mining tools, each edition of the report focuses on a different disease/treatment area, with the first targeting oncology. The study reveals China internet users generated ...
Alzheimer's disease is the most common cause of dementia. It is one of the principal causes of death worldwide and the second most common one among the over 70s, affecting 13 million people all over ...
-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback